Drug General Information (ID: DDI5E47WS8)
Drug Name			Trastuzumab		Drug Info		Doxorubicin (liposomal)		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Antineoplastics

Mechanism of Trastuzumab-Doxorubicin (liposomal) Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Trastuzumab				Doxorubicin (liposomal)
Mechanism		Cardiotoxic effects				Cardiotoxic effects
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Trastuzumab and Doxorubicin (liposomal)

Recommended Action
Management		Trastuzumab and cardiotoxic agents such as anthracyclines should not be used in combination except in settings where cardiac monitoring is possible. The use of anthracycline-based therapy should be avoided, if possible, for up to 7 months after stopping trastuzumab. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Strasser F, Betticher DC, Suter TM "Trastuzumab and breast cancer." N Engl J Med 345 (2001): 996.[PMID: 11575296]
3	Product Information. DOXOrubicin Hydrochloride (DOXOrubicin). Pfizer U.S. Pharmaceuticals Group, New York, NY.